DJIA 17,164.95 -251.90 -1.45%
NASDAQ 4,635.24 -48.17 -1.03%
S&P 500 1,994.99 -26.26 -1.30%
market minute promo

Galena Biopharma, Inc. (NASDAQ: GALE)

1.63 0.00 (0.00%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

GALE $1.63 0.00%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.63
Previous Close $1.63
Daily Range $1.60 - $1.66
52-Week Range $1.43 - $5.70
Market Cap $198.0M
P/E Ratio -2.14
Dividend (Yield) $0.00 (0.0%)
Volume 710,879
Average Daily Volume 1,743,785
Current FY EPS -$0.36

Sector

Healthcare

Industry

Drugs

Galena Biopharma, Inc. (GALE) Description

Galena Biopharma Inc is a biotechnology company focused on discovering developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics. Website: http://www.galenabiopharma.com/

News & Commentary

In Case You Missed It, Breast Cancer Detection Just Took a Gigantic Leap Forward

When battling breast cancer, time is of the essence. That's why the discovery of this new breast cancer detection technique really is that big of a deal.

Advaxis: Heavily Promoted And Misleading Investors

Galena Biopharma (GALE) Is Weak On High Volume Today

Galena Biopharma (GALE) Jumps: Stock Rises 9.1% - Tale of the Tape

Galena Biopharma (GALE) Jumps: Stock Rises 9.1% - Tale of the Tape

Adam Feuerstein's 2014 Biotech Stock Report Card (No Grading on a Curve)

Nominees for Absolute Worst Bio-Technology CEOs of 2014 Are ...

Galena: I Am Bullish, However, Nobody Has Paid Me For My Stance

Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Clinical Trial Data At The 56th A

Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Clinical Trial Data At The 56th American Society of

This is Incredibly Good News for Breast Cancer Survivors

A recently released study from Canada shines light on the advancements made in treating breast cancer over the past two decades.

Why Galena Biopharma Inc. Stock Sank 13% in November

Galena Biopharma stock sinks below $2 per share following a weaker-than-expected earnings report and an unfavorable financing deal.

See More GALE News...

GALE's Top Competitors

GALE $1.63 (0.00%)
Current stock: GALE
AMGN $152.26 (-2.63%)
Current stock: AMGN
GILD $104.83 (0.62%)
Current stock: GILD
BIIB $389.16 (10.17%)
Current stock: BIIB